[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-367374-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-367374-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","c12orf49-inhibits-ferroptosis-in-hepatocellular-carcinoma-cells-via-reprogramming-srebp1scd1-mediated-lipid-metabolism","C12ORF49 inhibits ferroptosis in hepatocellular carcinoma cells via reprogramming SREBP1/SCD1-mediated lipid metabolism","","C12ORF49 is reported as a regulator of sterol regulatory element binding proteins (SREBPs) that govern lipid biosynthesis, yet its function in human cancers remains unclear. The study finds higher C12ORF49 levels in hepatocellular carcinoma (HCC) tissues than in adjacent non-cancerous liver, with increased expression linked to poorer patient survival. Knockdown suppresses HCC cell survival and tumor growth by inducing ferroptosis, while overexpression shows the opposite effect. Mechanistically, C12ORF49 enhances SREBP1/SCD-mediated monounsaturated fatty acid production to inhibit ferroptosis, and C12ORF49 silencing synergizes with Sorafenib to promote HCC cell death, supporting C12ORF49 targeting to improve Sorafenib efficacy.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/c12orf49-inhibits-ferroptosis-in-hepatocellular-carcinoma-cells-via-reprogramming-srebp1scd1-mediated-lipid-metabolism/367374/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/c12orf49-inhibits-ferroptosis-in-hepatocellular-carcinoma-cells-via-reprogramming-srebp1scd1-mediated-lipid-metabolism/367374.png","ImageObject",300,407,{"name":42,"@type":43},"Jacob","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-25","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",10,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What relationship exists between C12ORF49 expression and HCC patient outcomes?","Question",{"text":63,"@type":64},"C12ORF49 levels are higher in HCC tissues than in adjacent non-cancerous liver, and increased C12ORF49 expression is associated with poorer survival in HCC patients.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How does C12ORF49 affect ferroptosis in hepatocellular carcinoma cells?",{"text":68,"@type":64},"C12ORF49 promotes SREBP1/SCD-regulated monounsaturated fatty acid production that inhibits ferroptosis; silencing induces ferroptosis while overexpression reduces it.",{"name":70,"@type":61,"acceptedAnswer":71},"What is the observed effect of combining C12ORF49 silencing with Sorafenib?",{"text":72,"@type":64},"Silencing C12ORF49 together with Sorafenib treatment shows a synergistic effect in inducing HCC cell death.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},367374,1790211486,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":55,"slug":125},"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":113,"preview_page_count":33,"preview_urls":145},962084931830,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","[www.nature.com/cddiscovery](www.nature.com/cddiscovery)  \nARTICLE OPEN   \nC12ORF49 inhibits ferroptosis in hepatocellular carcinoma cells via reprogramming SREBP1/SCD1-mediated lipid metabolism  \nHeng-Chao Yu 1,4 ✉, Liang Jin 1,4, Lu Bai2,4, Yu-Jia Zhang3,4 and Zhao-Xu Yang1 ✉  \n© The Author(s) 2025  \n|  |  |  |\n| --- | --- | --- |\n|  | Altered lipid metabolism is an emerging hallmark of cancer, which is involved in various aspects of the cancer phenotypes. C12ORF49 has recently been identiﬁed as a pivotal regulator of sterol regulatory element binding proteins (SREBPs), a family of transcriptional factors that govern lipid biosynthesis. Nevertheless, the function of C12ORF49 in human cancers has not been studied. Here, we show that C12ORF49 levels are higher in HCC tissue than in nearby non-cancerous liver tissue. Additionally, increased C12ORF49 expression is linked to poorer survival outcomes in HCC patients. Functional experiments uncovered that knockdown of C12ORF49 inhibited HCC cell survival and tumor growth by inducing ferroptosis, whereas the opposites were observed upon C12ORF49 overexpression. Mechanistically, C12ORF49 promotes SREBP1/SCD-regulated production of monounsaturated fatty acids, which inhibits ferroptosis in HCC cells. Furthermore, silencing C12ORF49 combined with Sorafenib treatment showed a synergistic effect in inducing HCC cell death. Together, our ﬁndings suggest a critical role of C12ORF49 in the evasion of ferroptosis in HCC cells, highlighting the potential of targeting C12ORF49 as a therapeutic strategy to enhance the |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n| efﬁcacy of Sorafenib treatment in HCC. |  |  |\n|  | Cell Death Discovery (2025)11:178; [https://doi.org/10.1038/s41420-025-02480-2](https://doi.org/10.1038/s41420-025-02480-2) |  |\n|  |  |  |\n\nINTRODUCTION  \nDespite recent advances in surgical treatment and systemic chemotherapy, hepatocellular carcinoma (HCC) patients still face a poor prognosis [1], primarily because of late-stage diagnoses [2, 3] . Sorafenib, the ﬁrst FDA-approved multitargeted tyrosine kinase inhibitor, has been recommended for treating advanced HCC [4] . Recently, there has been signiﬁcant focus on Sorafenib’s crucial role in promoting cell apoptosis, especially ferroptosis [5] . Nevertheless, the therapeutic effectiveness of Sorafenib is hindered by the emergence of drug resistance [6, 7] . Therefore, there is an urgent need to identify the factors that contribute to this resistance in order to enhance treatment efﬁcacy.  \nCancer cells undergo alterations in lipid metabolism, which are primarily characterized an increase in de novo lipogenesis to support their rapid growth and metastasis [8–10]. Unfortunately, how cancer cells altered lipid metabolism remain inadequately elucidated. Several critical fatty acid biosynthesis enzymes, ATPcitrate lyase (ACLY) [11], fatty acid synthase (FAS) [12], acetyl-CoA carboxylase (ACC) [13] and stearoyl-Coenzyme a desaturase 1 (SCD1)  \n[14], as well as pivotal cholesterol biosynthesis enzymes, 3-hydroxy- 3-methylglutaryl-CoA synthase 1 (HMGCS1) and 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR) [15, 16], were upregulated and facilitates the occurrence and development of multiple cancer types. These fatty acid and cholesterol synthesis enzymes are primarily regulated by SREBP1 and SREBP-2 [17, 18]. It is well known that SREBP1 and SREBP2 are produced as inactive precursors located in the cytoplasm. The proteolytic activation of SREBP1 and SREBP2  \nrequires their translocation from the endoplasmic reticulum to the Golgi, where undergo sequential cleavage by site-1 protease (S1P) and site-2 protease (S1P), leading to their translocation to the nucleus to modulate the expressions of target genes [18]. Recently, C12ORF49 was reported as an important regulator of SREBP signaling by facilitating S1P activation [19]. Ablation of C12ORF49 resulted in diminished maturation of ","cbCaidI96vLE36jP","https://ap.wps.com/l/cbCaidI96vLE36jP","pdf",6270654,12,"English","# Introduction\n## Altered lipid metabolism and cancer prognosis\n# Results\n## Elevated C12ORF49 predicts poor survival\n## C12ORF49 effects on HCC ferroptosis and growth\n## Synergy with Sorafenib treatment","[{\"question\":\"What relationship exists between C12ORF49 expression and HCC patient outcomes?\",\"answer\":\"C12ORF49 levels are higher in HCC tissues than in adjacent non-cancerous liver, and increased C12ORF49 expression is associated with poorer survival in HCC patients.\"},{\"question\":\"How does C12ORF49 affect ferroptosis in hepatocellular carcinoma cells?\",\"answer\":\"C12ORF49 promotes SREBP1/SCD-regulated monounsaturated fatty acid production that inhibits ferroptosis; silencing induces ferroptosis while overexpression reduces it.\"},{\"question\":\"What is the observed effect of combining C12ORF49 silencing with Sorafenib?\",\"answer\":\"Silencing C12ORF49 together with Sorafenib treatment shows a synergistic effect in inducing HCC cell death.\"}]","C12ORF49 inhibits ferroptosis in hepatocellular carcinoma cells via reprogramming SREBP1/SCD1-mediated lipid metabolism | PDF",1790170510,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6dd4f97cc0c8feaf087023292130af64.webp",983,1305,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/07691b340d37817c46f2f2386c3b05f2.webp",982,1304,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3bc3576956f8db18b6cac8ea1c3b0447.webp",981,1303,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2383a3a7b39fb4ca808314d4c80749d1.webp",980,1301]